查看购物车
  • Traditional Chinese
  • English
  • Japanese
封面
市场调查报告书
商品编码
1722409

2025-2033年眼科药物市场报告（按类型、药品类别、适应症、剂型、配销通路和地区）

Ophthalmic Drugs Market Report by Type, Drug Class, Indication, Dosage Form, Distribution Channel, and Region 2025-2033
出版日期: | 出版商: IMARC | 英文 150 Pages | 商品交期: 2-3个工作天内

价格

2024年全球眼科药物市场规模达472亿美元。展望未来， IMARC Group预计到2033年市场规模将达到712亿美元，2025-2033年期间的成长率（CAGR）为4.44%。市场受到以下因素的推动：被诊断患有眼疾的人数不断增加、药物输送系统的重大技术进步、政府的有利倡议和资金、老年人口的增加以及糖尿病患者人数的增加。

眼科药物市场分析：

主要市场驱动因素：与眼睛相关的问题的日益增多、药物配方的重大发展以及对技术和药物研究领域的强劲投资是推动眼科药物成长的一些主要市场驱动因素。

主要市场趋势：选择联合疗法的个人数量不断增加、行业参与者之间的策略伙伴关係不断增加、以及对创造以前被认为无法治疗的疾病的治疗方法的日益重视是眼科药物市场的一些趋势。

地理趋势：北美以其强大的医疗保健基础设施和不断增加的糖尿病相关眼部疾病诊断数量引领市场。该产业的第二大市场是欧洲，因为欧洲老龄人口不断增加，且该地区的研发活动不断增加。

竞争格局：AbbVie Inc.、Aerie Pharmaceuticals Inc.、Akorn Inc.、Alcon、Bausch Health Companies Inc.、Bayer AG、F. Hoffmann-La Roche AG、Johnson & Johnson、Merck & Co. Inc.、Novartis AG、Regeneron Pharmaceticals Inc.、Santenticals.

挑战与机会：该市场的挑战包括严格的监管环境，导致药品审批延迟和开发的眼科药物成本上升。此外，眼科药物市场近期的机会包括因医疗保健管道不断扩大而产生的新兴市场潜力。

眼科药物市场趋势：

个人眼部疾病盛行率上升

全球范围内日益增多的眼部问题大大增加了眼科药物的需求。根据资料，白内障、青光眼、老年黄斑部病变（AMD）和糖尿病视网膜病变等疾病正在推动市场发展。根据世界卫生组织 (WHO) 的数据，每年至少有 22 亿人患有近视或远视障碍。报告也指出，至少有 10 亿视力障碍病例本来是可以避免的，或尚未预防。患有眼部疾病的人数不断增加，导致对抗青光眼药物、抗 VEGF 药物和抗发炎药物等治疗药物的需求大幅增加。大量市场研究报告支持这种相关性，这些报告描述了有前景的先进治疗方案并促进了眼科药物市场最近的发展活动。

药物输送系统的重大技术进步

药物输送系统的创新可以归功于新技术，这是创造积极的眼科药物市场前景的主要因素。微乳剂、奈米技术或眼部插入物等新配方可提供更好的功效、安全性和患者依从性。例如，奈米级的药物载体可以显着提高药物对目标眼组织的生物利用度，从而减少频繁服药的需要以及与药物相关的任何副作用。因此，越来越多的公司正在投资这些技术以在市场上获得竞争优势。业内新型眼科给药系统专利数量不断增加。所有上述研发 (R&D) 投资均以受益于新药物输送技术的细分市场的市场成长预测为基础。这意味着他们有能力显着颠覆目前的眼科治疗模式。

政府的优惠措施和资金

政府政策是创造积极眼科药物市场前景的重要因素。世界各国政府已推出各种措施来改善医疗保健基础设施，包括使有效的眼科护理更容易获得。例如，许多国家提供机会资助开设和发展眼科保健中心、投资研究开发新药以及传播有关眼科疾病的讯息。在美国，国家眼科研究所为眼科领域的研究提供了大量资金。这推动了该领域的重大突破，为良好视力产业开闢了新的药物和机会。此外，透过 FDA 的突破性疗法认定等途径加快药物审批，提高了有远见的眼科解决方案的市场准入。

目录

第一章：前言

第二章：范围与方法

  • 研究目标
  • 利害关係人
  • 资料来源
    • 主要来源
    • 次要来源
  • 市场评估
    • 自下而上的方法
    • 自上而下的方法
  • 预测方法

第三章：执行摘要

第四章：简介

  • 概述
  • 主要行业趋势

第五章：全球眼科药物市场

  • 市场概览
  • 市场表现
  • COVID-19的影响
  • 市场预测

第六章：市场细分：依类型

  • 处方药
  • 非处方药

第七章：市场区隔：依药品类别

  • 抗青光眼
  • 抗感染
  • 抗发炎
  • 抗过敏
  • 其他的

第八章：市场区隔：依指标

  • 干眼症
  • 青光眼
  • 感染/发炎/过敏
  • 视网膜疾病
  • 其他的

第九章：市场区隔：按剂型

  • 液体眼科药物剂型
  • 固体眼科药物剂型
  • 半固体眼科药物剂型
  • 多室药物输送系统
  • 其他的

第十章：市场区隔：按配销通路

  • 医院药房
  • 药局
  • 网路药局
  • 其他的

第 11 章：市场区隔：按地区

  • 北美洲
    • 美国
    • 加拿大
  • 亚太
    • 中国
    • 日本
    • 印度
    • 韩国
    • 澳洲
    • 印尼
    • 其他的
  • 欧洲
    • 德国
    • 法国
    • 英国
    • 义大利
    • 西班牙
    • 俄罗斯
    • 其他的
  • 拉丁美洲
    • 巴西
    • 墨西哥
    • 其他的
  • 中东和非洲
    • 市场区隔：依国家

第 12 章：SWOT 分析

  • 概述
  • 优势
  • 弱点
  • 机会
  • 威胁

第 13 章：价值链分析

第 14 章：波特五力分析

  • 概述
  • 买家的议价能力
  • 供应商的议价能力
  • 竞争程度
  • 新进入者的威胁
  • 替代品的威胁

第 15 章：价格分析

第 16 章：竞争格局

  • 市场结构
  • 关键参与者
  • 关键参与者简介
    • AbbVie Inc.
    • Aerie Pharmaceuticals Inc.
    • Akorn Inc.
    • Alcon
    • Bausch Health Companies Inc.
    • Bayer AG
    • F. Hoffmann-La Roche AG
    • Johnson & Johnson
    • Merck & Co. Inc.
    • Novartis AG
    • Regeneron Pharmaceuticals Inc.
    • Santen Pharmaceutical Co. Ltd.
    • Sun Pharmaceutical Industries Ltd.
Product Code: SR112025A5287

The global ophthalmic drugs market size reached USD 47.2 Billion in 2024. Looking forward, IMARC Group expects the market to reach USD 71.2 Billion by 2033, exhibiting a growth rate (CAGR) of 4.44% during 2025-2033. The market is propelled by the rising number of individuals diagnosed with eye diseases, significant technological advancements in drug delivery systems, favorable government initiatives and funding, rising geriatric population, and increasing number of individuals suffering with diabetes.

Ophthalmic Drugs Market Analysis:

Major Market Drivers: The rising issues related to eyes, significant developments in drug formulations, and robust investment in technology and pharmaceutical research sectors are some of the major market drivers driving the ophthalmic drugs growth.

Key Market Trends: The rising number of individuals opting for combination therapies, increasing strategic partnerships among industry players, and the rising emphasis on creating treatments for conditions that were considered untreatable previously are some of the ophthalmic drugs market trends.

Geographical Trends: North America leads the market on account of a strong healthcare infrastructure and the increasing amount of diagnosis of diabetes-related eye conditions. The second largest market of the industry is Europe due to its rising aging population and increasing research and development (R&D) activities across the region.

Competitive Landscape: AbbVie Inc., Aerie Pharmaceuticals Inc., Akorn Inc., Alcon, Bausch Health Companies Inc., Bayer AG, F. Hoffmann-La Roche AG, Johnson & Johnson, Merck & Co. Inc., Novartis AG, Regeneron Pharmaceuticals Inc., Santen Pharmaceutical Co. Ltd. and Sun Pharmaceutical Industries Ltd, are among some of the key players in the ophthalmic drugs industry.

Challenges and Opportunities: Challenges of this market include the strict regulatory environments which lead to a delay in drug approvals and rising cost of developed ophthalmic drugs. Moreover, ophthalmic drugs market recent opportunities include the potential of the emerging markets accredited to the rising healthcare access.

Ophthalmic Drugs Market Trends:

Rising Prevalence of Eye Diseases Among Individuals

The increasing eye-related issues worldwide are majorly escalating the ophthalmic drugs demand. As per the data, illnesses such as cataracts, glaucoma, age-related macular degeneration (AMD), and diabetic retinopathy are driving the market. According to the WORLD HEALTH ORGANIZATION (WHO), at least 2.2 Billion individuals each year have a near of distance vision impairment. The report also states that minimum 1 Billion of these cases of vision impairment could have been avoided or is yet to be prevented. The rising number of individuals with eye diseases are significantly leading to a rise in the demand for these therapeutic drugs such as anti-glaucoma medications, anti-VEGF agents, and anti-inflammatory agents. This correlation is supported by numerous market research reports which depict promising advanced treatment solutions and promote ophthalmic drugs market recent development activities.

Significant Technological Advancements in Drug Delivery Systems

The innovation of drug delivery systems, which can be accredited to novel technologies has been a major factor in creating a positive ophthalmic drugs market overview. New formulation possibilities such as microemulsions, nanotechnology, or ocular inserts offer better efficacy, safety, and patient adherence. For instance, drug carriers at a nano-size scale can significantly improve the bioavailability of the drug to the targeted ocular tissues, thereby reducing the need for frequent dosing and any side effects associated with the drug. As a result, more companies are investing in these technologies in order to gain a competitive edge in the market. There is a growing number of novel ophthalmic drug delivery system patents in the industry. All of the aforementioned research and development (R&D) investments are underpinned by the projections of market growth within the segments that benefit from new drug delivery technologies. This implies their ability to significantly disrupt the present ophthalmology treatment paradigm.

Favorable Government Initiatives and Funding

Government policies and act as a vital factor creating a positive ophthalmic drugs market outlook. Governments worldwide have launched various initiatives to improve healthcare infrastructure, including making effective eye care more accessible. For instance, numerous countries provide opportunities for subsidizing the opening and development of eye care centers, investing in research to create new drugs, and spreading information about eye diseases. In the United States, the National Eye Institute provides significant funding for research in the ophthalmic field. This propels a significant breakthrough in this area, opening up new drugs and opportunities in the industry for good vision. Moreover, faster drug approvals through routes such as FDA's Breakthrough Therapy designation improve market entry for visionary ophthalmic solutions.

Ophthalmic Drugs Industry Segmentation:

Breakup by Type:

  • Prescription Drugs
  • Over-the-counter Drugs

Prescription drugs accounts for the majority of the market share

The highest ophthalmic drugs market revenue is deriving from prescription drugs. This can be accredited to the requirement of regulated forms of treatment for certain complex or severe eye disorders. Glaucoma, age-regulated macular degeneration, diabetic retinopathy, and many other conditions are typically treated with prescription medication that must be administered in precise dosages and only used through patient monitoring by a healthcare provider. Age-related macular degeneration can be categorized as dry AMD and wet AMD, and is a primary case of vision loss in individuals 50 years or older. Approximately 80% of individuals (8 out of 10) are diagnosed with dry form AMD. The rapid growth of the patient population proves the irreplaceability of prescription drugs in successful disease treatment and therapy.

Breakup by Drug Class:

  • Anti-glaucoma
  • Anti-infection
  • Anti-inflammation
  • Anti-allergy
  • Others

Anti-glaucoma holds the largest share in the industry

The largest ophthalmic drugs market share is held by anti-glaucoma drugs, where glaucoma is the second leading cause of irreversible blindness globally. According to the NATIONAL INSTITUE OF HEALTH (NIH), the number of individuals suffering with glaucoma globally will rise upto 111.8 million by 2040. A rapidly growing glaucoma patient population signifies that patients need effective therapeutics on a long-term basis in order to maintain visual function, and hence there is significant demand for this segment. Additionally, drug formulation is constantly being developed to achieve maximum relief for glaucoma patients and compliance with the treatment on the part of the patient.

Breakup by Indication:

  • Dry Eye
  • Glaucoma
  • Infection/Inflammation/Allergy
  • Retinal Disorders
  • Others

Retinal disorders represent the leading market segment

Retinal disorders account for a large part of the ophthalmic drugs market, mainly due to the high frequency of diseases and their severity, which includes diabetic retinopathy and age-related macular degeneration. As per a report published by the NATIONAL INSTITUE OF HEALTH (NIH), individuals diagnosed with type 1, type 2, and gestational diabetes are more prone to diabetic retinopathy. The report also suggested that diabetic retinopathy can also lead to other serious eye conditions, such as diabetic macular edema and neovascular glaucoma. With time, approximately 1 in 15 individuals with diabetes develop DME. In the absence of treatment, these diseases often lead to complete blindness and require constant drug support, due to which the consumption of drugs in this segment is significant.

Breakup by Dosage Form:

  • Liquid Ophthalmic Drug Forms
  • Solid Ophthalmic Drug Forms
  • Semisolid Ophthalmic Drug Forms
  • Multicompartment Drug Delivery Systems
  • Others

Liquid ophthalmic drug forms exhibit a clear dominance in the market

On account of the need for easily administered and fast-acting medication directly into the eye, liquid ophthalmic drugs are the largest segment in the market by dosage form. Liquid dosage forms include drops, solutions, tinctures, injections, tinctures, elixirs, and syrups. Considering the relatively wide range of methods for delivering liquid medication into the eye, drops are the most prevalent, offering better controllability of dosage and higher patient adherence, thus impelling the ophthalmic drugs market growth. As per the NATIONAL INSTITUTE OF HEALTH (NIH), demand for liquid ophthalmic formulations is prominently high, with 90% of prescribed medications being eye drops. It is also driven by the introduction of non-preserved and multi-dose packaging, which increases convenience and safety. Thus, liquid formulations are widely preferred by patient and healthcare providers in cases of eye conditions.

Breakup by Distribution Channel:

  • Hospital Pharmacies
  • Drug Stores
  • Online Pharmacies
  • Others

Hospital pharmacies dominates the market

In the market breakup by distribution channel, hospital pharmacies currently constitute the largest segment. The factor dictating this is the direct integration of these pharmacies into the healthcare facilities and immediate patient care. As a result, patients have timely access to the ophthalmic medications prescribed by their ophthalmologists. Early treatment of acute and chronic eye conditions is essential to prevent vision impairment and blindness. Hospital pharmacies, in turn, are the first to receive new drug approvals, given their affiliation with manufacturers and the purchasing power. As a result, the drug distribution and administration process are facilitated, patient adherence improves, and outcomes enhance.

Breakup by Region:

  • North America
  • United States
  • Canada
  • Asia-Pacific
  • China
  • Japan
  • India
  • South Korea
  • Australia
  • Indonesia
  • Others
  • Europe
  • Germany
  • France
  • United Kingdom
  • Italy
  • Spain
  • Russia
  • Others
  • Latin America
  • Brazil
  • Mexico
  • Others
  • Middle East and Africa

North America leads the market, accounting for the largest ophthalmic drugs market share

The market research report has also provided a comprehensive analysis of all the major regional markets, which include North America (the United States and Canada); Asia Pacific (China, Japan, India, South Korea, Australia, Indonesia, and others); Europe (Germany, France, the United Kingdom, Italy, Spain, Russia, and others); Latin America (Brazil, Mexico, and others); and the Middle East and Africa. According to the report, North America accounted for the largest market share.

North America holds the largest market share due to the developed healthcare system of the region, high healthcare expenditures, and strong presence of big pharma. Moreover, the eye disease rate in the North is high due to glaucoma, for instance, according to the NATIONAL HEALTH INSTITUE (NIH), 3 million individuals in the United States are affected by glaucoma. Another prominent reason is the sponsorship of the United States in medical research, with eye treatment gaining notable financial support.

Competitive Landscape:

The ophthalmic drugs market report has also provided a comprehensive analysis of the competitive landscape in the market. Detailed profiles of all major companies have also been provided. Some of the major market players in the metal fiber industry include AbbVie Inc., Aerie Pharmaceuticals Inc., Akorn Inc., Alcon, Bausch Health Companies Inc., Bayer AG, F. Hoffmann-La Roche AG, Johnson & Johnson, Merck & Co. Inc., Novartis AG, Regeneron Pharmaceuticals Inc., Santen Pharmaceutical Co. Ltd. and Sun Pharmaceutical Industries Ltd.

Key Questions Answered in This Report

  • 1.How big is the ophthalmic drugs market?
  • 2.What is the future outlook of ophthalmic drugs market?
  • 3.What are the key factors driving the ophthalmic drugs market?
  • 4.Which region accounts for the largest ophthalmic drugs market share?
  • 5.Which are the leading companies in the global ophthalmic drugs market?

Table of Contents

1 Preface

2 Scope and Methodology

  • 2.1 Objectives of the Study
  • 2.2 Stakeholders
  • 2.3 Data Sources
    • 2.3.1 Primary Sources
    • 2.3.2 Secondary Sources
  • 2.4 Market Estimation
    • 2.4.1 Bottom-Up Approach
    • 2.4.2 Top-Down Approach
  • 2.5 Forecasting Methodology

3 Executive Summary

4 Introduction

  • 4.1 Overview
  • 4.2 Key Industry Trends

5 Global Ophthalmic Drugs Market

  • 5.1 Market Overview
  • 5.2 Market Performance
  • 5.3 Impact of COVID-19
  • 5.4 Market Forecast

6 Market Breakup by Type

  • 6.1 Prescription Drugs
    • 6.1.1 Market Trends
    • 6.1.2 Market Forecast
  • 6.2 Over-the-counter Drugs
    • 6.2.1 Market Trends
    • 6.2.2 Market Forecast

7 Market Breakup by Drug Class

  • 7.1 Anti-glaucoma
    • 7.1.1 Market Trends
    • 7.1.2 Market Forecast
  • 7.2 Anti-infection
    • 7.2.1 Market Trends
    • 7.2.2 Market Forecast
  • 7.3 Anti-inflammation
    • 7.3.1 Market Trends
    • 7.3.2 Market Forecast
  • 7.4 Anti-allergy
    • 7.4.1 Market Trends
    • 7.4.2 Market Forecast
  • 7.5 Others
    • 7.5.1 Market Trends
    • 7.5.2 Market Forecast

8 Market Breakup by Indication

  • 8.1 Dry Eye
    • 8.1.1 Market Trends
    • 8.1.2 Market Forecast
  • 8.2 Glaucoma
    • 8.2.1 Market Trends
    • 8.2.2 Market Forecast
  • 8.3 Infection/Inflammation/Allergy
    • 8.3.1 Market Trends
    • 8.3.2 Market Forecast
  • 8.4 Retinal Disorders
    • 8.4.1 Market Trends
    • 8.4.2 Market Forecast
  • 8.5 Others
    • 8.5.1 Market Trends
    • 8.5.2 Market Forecast

9 Market Breakup by Dosage Form

  • 9.1 Liquid Ophthalmic Drug Forms
    • 9.1.1 Market Trends
    • 9.1.2 Market Forecast
  • 9.2 Solid Ophthalmic Drug Forms
    • 9.2.1 Market Trends
    • 9.2.2 Market Forecast
  • 9.3 Semisolid Ophthalmic Drug Forms
    • 9.3.1 Market Trends
    • 9.3.2 Market Forecast
  • 9.4 Multicompartment Drug Delivery Systems
    • 9.4.1 Market Trends
    • 9.4.2 Market Forecast
  • 9.5 Others
    • 9.5.1 Market Trends
    • 9.5.2 Market Forecast

10 Market Breakup by Distribution Channel

  • 10.1 Hospital Pharmacies
    • 10.1.1 Market Trends
    • 10.1.2 Market Forecast
  • 10.2 Drug Stores
    • 10.2.1 Market Trends
    • 10.2.2 Market Forecast
  • 10.3 Online Pharmacies
    • 10.3.1 Market Trends
    • 10.3.2 Market Forecast
  • 10.4 Others
    • 10.4.1 Market Trends
    • 10.4.2 Market Forecast

11 Market Breakup by Region

  • 11.1 North America
    • 11.1.1 United States
      • 11.1.1.1 Market Trends
      • 11.1.1.2 Market Forecast
    • 11.1.2 Canada
      • 11.1.2.1 Market Trends
      • 11.1.2.2 Market Forecast
  • 11.2 Asia-Pacific
    • 11.2.1 China
      • 11.2.1.1 Market Trends
      • 11.2.1.2 Market Forecast
    • 11.2.2 Japan
      • 11.2.2.1 Market Trends
      • 11.2.2.2 Market Forecast
    • 11.2.3 India
      • 11.2.3.1 Market Trends
      • 11.2.3.2 Market Forecast
    • 11.2.4 South Korea
      • 11.2.4.1 Market Trends
      • 11.2.4.2 Market Forecast
    • 11.2.5 Australia
      • 11.2.5.1 Market Trends
      • 11.2.5.2 Market Forecast
    • 11.2.6 Indonesia
      • 11.2.6.1 Market Trends
      • 11.2.6.2 Market Forecast
    • 11.2.7 Others
      • 11.2.7.1 Market Trends
      • 11.2.7.2 Market Forecast
  • 11.3 Europe
    • 11.3.1 Germany
      • 11.3.1.1 Market Trends
      • 11.3.1.2 Market Forecast
    • 11.3.2 France
      • 11.3.2.1 Market Trends
      • 11.3.2.2 Market Forecast
    • 11.3.3 United Kingdom
      • 11.3.3.1 Market Trends
      • 11.3.3.2 Market Forecast
    • 11.3.4 Italy
      • 11.3.4.1 Market Trends
      • 11.3.4.2 Market Forecast
    • 11.3.5 Spain
      • 11.3.5.1 Market Trends
      • 11.3.5.2 Market Forecast
    • 11.3.6 Russia
      • 11.3.6.1 Market Trends
      • 11.3.6.2 Market Forecast
    • 11.3.7 Others
      • 11.3.7.1 Market Trends
      • 11.3.7.2 Market Forecast
  • 11.4 Latin America
    • 11.4.1 Brazil
      • 11.4.1.1 Market Trends
      • 11.4.1.2 Market Forecast
    • 11.4.2 Mexico
      • 11.4.2.1 Market Trends
      • 11.4.2.2 Market Forecast
    • 11.4.3 Others
      • 11.4.3.1 Market Trends
      • 11.4.3.2 Market Forecast
  • 11.5 Middle East and Africa
    • 11.5.1 Market Trends
    • 11.5.2 Market Breakup by Country
    • 11.5.3 Market Forecast

12 SWOT Analysis

  • 12.1 Overview
  • 12.2 Strengths
  • 12.3 Weaknesses
  • 12.4 Opportunities
  • 12.5 Threats

13 Value Chain Analysis

14 Porters Five Forces Analysis

  • 14.1 Overview
  • 14.2 Bargaining Power of Buyers
  • 14.3 Bargaining Power of Suppliers
  • 14.4 Degree of Competition
  • 14.5 Threat of New Entrants
  • 14.6 Threat of Substitutes

15 Price Analysis

16 Competitive Landscape

  • 16.1 Market Structure
  • 16.2 Key Players
  • 16.3 Profiles of Key Players
    • 16.3.1 AbbVie Inc.
      • 16.3.1.1 Company Overview
      • 16.3.1.2 Product Portfolio
      • 16.3.1.3 Financials
      • 16.3.1.4 SWOT Analysis
    • 16.3.2 Aerie Pharmaceuticals Inc.
      • 16.3.2.1 Company Overview
      • 16.3.2.2 Product Portfolio
      • 16.3.2.3 Financials
    • 16.3.3 Akorn Inc.
      • 16.3.3.1 Company Overview
      • 16.3.3.2 Product Portfolio
    • 16.3.4 Alcon
      • 16.3.4.1 Company Overview
      • 16.3.4.2 Product Portfolio
      • 16.3.4.3 Financials
    • 16.3.5 Bausch Health Companies Inc.
      • 16.3.5.1 Company Overview
      • 16.3.5.2 Product Portfolio
    • 16.3.6 Bayer AG
      • 16.3.6.1 Company Overview
      • 16.3.6.2 Product Portfolio
      • 16.3.6.3 Financials
      • 16.3.6.4 SWOT Analysis
    • 16.3.7 F. Hoffmann-La Roche AG
      • 16.3.7.1 Company Overview
      • 16.3.7.2 Product Portfolio
      • 16.3.7.3 SWOT Analysis
    • 16.3.8 Johnson & Johnson
      • 16.3.8.1 Company Overview
      • 16.3.8.2 Product Portfolio
      • 16.3.8.3 Financials
      • 16.3.8.4 SWOT Analysis
    • 16.3.9 Merck & Co. Inc.
      • 16.3.9.1 Company Overview
      • 16.3.9.2 Product Portfolio
      • 16.3.9.3 Financials
      • 16.3.9.4 SWOT Analysis
    • 16.3.10 Novartis AG
      • 16.3.10.1 Company Overview
      • 16.3.10.2 Product Portfolio
      • 16.3.10.3 Financials
      • 16.3.10.4 SWOT Analysis
    • 16.3.11 Regeneron Pharmaceuticals Inc.
      • 16.3.11.1 Company Overview
      • 16.3.11.2 Product Portfolio
      • 16.3.11.3 Financials
      • 16.3.11.4 SWOT Analysis
    • 16.3.12 Santen Pharmaceutical Co. Ltd.
      • 16.3.12.1 Company Overview
      • 16.3.12.2 Product Portfolio
    • 16.3.13 Sun Pharmaceutical Industries Ltd.
      • 16.3.13.1 Company Overview
      • 16.3.13.2 Product Portfolio

List of Figures

  • Figure 1: Global: Ophthalmic Drugs Market: Major Drivers and Challenges
  • Figure 2: Global: Ophthalmic Drugs Market: Sales Value (in Billion USD), 2019-2024
  • Figure 3: Global: Ophthalmic Drugs Market Forecast: Sales Value (in Billion USD), 2025-2033
  • Figure 4: Global: Ophthalmic Drugs Market: Breakup by Type (in %), 2024
  • Figure 5: Global: Ophthalmic Drugs Market: Breakup by Drug Class (in %), 2024
  • Figure 6: Global: Ophthalmic Drugs Market: Breakup by Indication (in %), 2024
  • Figure 7: Global: Ophthalmic Drugs Market: Breakup by Dosage Form (in %), 2024
  • Figure 8: Global: Ophthalmic Drugs Market: Breakup by Distribution Channel (in %), 2024
  • Figure 9: Global: Ophthalmic Drugs Market: Breakup by Region (in %), 2024
  • Figure 10: Global: Ophthalmic Drugs (Prescription Drugs) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 11: Global: Ophthalmic Drugs (Prescription Drugs) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 12: Global: Ophthalmic Drugs (Over-the-counter Drugs) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 13: Global: Ophthalmic Drugs (Over-the-counter Drugs) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 14: Global: Ophthalmic Drugs (Anti-glaucoma) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 15: Global: Ophthalmic Drugs (Anti-glaucoma) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 16: Global: Ophthalmic Drugs (Anti-infection) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 17: Global: Ophthalmic Drugs (Anti-infection) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 18: Global: Ophthalmic Drugs (Anti-inflammation) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 19: Global: Ophthalmic Drugs (Anti-inflammation) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 20: Global: Ophthalmic Drugs (Anti-allergy) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 21: Global: Ophthalmic Drugs (Anti-allergy) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 22: Global: Ophthalmic Drugs (Other Drug Classes) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 23: Global: Ophthalmic Drugs (Other Drug Classes) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 24: Global: Ophthalmic Drugs (Dry Eye) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 25: Global: Ophthalmic Drugs (Dry Eye) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 26: Global: Ophthalmic Drugs (Glaucoma) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 27: Global: Ophthalmic Drugs (Glaucoma) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 28: Global: Ophthalmic Drugs (Infection/Inflammation/Allergy) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 29: Global: Ophthalmic Drugs (Infection/Inflammation/Allergy) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 30: Global: Ophthalmic Drugs (Retinal Disorders) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 31: Global: Ophthalmic Drugs (Retinal Disorders) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 32: Global: Ophthalmic Drugs (Other Indications) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 33: Global: Ophthalmic Drugs (Other Indications) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 34: Global: Ophthalmic Drugs (Liquid Ophthalmic Drug Forms) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 35: Global: Ophthalmic Drugs (Liquid Ophthalmic Drug Forms) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 36: Global: Ophthalmic Drugs (Solid Ophthalmic Drug Forms) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 37: Global: Ophthalmic Drugs (Solid Ophthalmic Drug Forms) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 38: Global: Ophthalmic Drugs (Semisolid Ophthalmic Drug Forms) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 39: Global: Ophthalmic Drugs (Semisolid Ophthalmic Drug Forms) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 40: Global: Ophthalmic Drugs (Multicompartment Drug Delivery Systems) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 41: Global: Ophthalmic Drugs (Multicompartment Drug Delivery Systems) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 42: Global: Ophthalmic Drugs (Other Dosage Forms) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 43: Global: Ophthalmic Drugs (Other Dosage Forms) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 44: Global: Ophthalmic Drugs (Hospital Pharmacies) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 45: Global: Ophthalmic Drugs (Hospital Pharmacies) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 46: Global: Ophthalmic Drugs (Drug Stores) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 47: Global: Ophthalmic Drugs (Drug Stores) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 48: Global: Ophthalmic Drugs (Online Pharmacies) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 49: Global: Ophthalmic Drugs (Online Pharmacies) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 50: Global: Ophthalmic Drugs (Other Distribution Channels) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 51: Global: Ophthalmic Drugs (Other Distribution Channels) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 52: North America: Ophthalmic Drugs Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 53: North America: Ophthalmic Drugs Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 54: United States: Ophthalmic Drugs Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 55: United States: Ophthalmic Drugs Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 56: Canada: Ophthalmic Drugs Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 57: Canada: Ophthalmic Drugs Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 58: Asia-Pacific: Ophthalmic Drugs Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 59: Asia-Pacific: Ophthalmic Drugs Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 60: China: Ophthalmic Drugs Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 61: China: Ophthalmic Drugs Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 62: Japan: Ophthalmic Drugs Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 63: Japan: Ophthalmic Drugs Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 64: India: Ophthalmic Drugs Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 65: India: Ophthalmic Drugs Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 66: South Korea: Ophthalmic Drugs Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 67: South Korea: Ophthalmic Drugs Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 68: Australia: Ophthalmic Drugs Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 69: Australia: Ophthalmic Drugs Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 70: Indonesia: Ophthalmic Drugs Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 71: Indonesia: Ophthalmic Drugs Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 72: Others: Ophthalmic Drugs Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 73: Others: Ophthalmic Drugs Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 74: Europe: Ophthalmic Drugs Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 75: Europe: Ophthalmic Drugs Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 76: Germany: Ophthalmic Drugs Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 77: Germany: Ophthalmic Drugs Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 78: France: Ophthalmic Drugs Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 79: France: Ophthalmic Drugs Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 80: United Kingdom: Ophthalmic Drugs Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 81: United Kingdom: Ophthalmic Drugs Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 82: Italy: Ophthalmic Drugs Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 83: Italy: Ophthalmic Drugs Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 84: Spain: Ophthalmic Drugs Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 85: Spain: Ophthalmic Drugs Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 86: Russia: Ophthalmic Drugs Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 87: Russia: Ophthalmic Drugs Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 88: Others: Ophthalmic Drugs Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 89: Others: Ophthalmic Drugs Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 90: Latin America: Ophthalmic Drugs Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 91: Latin America: Ophthalmic Drugs Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 92: Brazil: Ophthalmic Drugs Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 93: Brazil: Ophthalmic Drugs Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 94: Mexico: Ophthalmic Drugs Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 95: Mexico: Ophthalmic Drugs Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 96: Others: Ophthalmic Drugs Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 97: Others: Ophthalmic Drugs Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 98: Middle East and Africa: Ophthalmic Drugs Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 99: Middle East and Africa: Ophthalmic Drugs Market: Breakup by Country (in %), 2024
  • Figure 100: Middle East and Africa: Ophthalmic Drugs Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 101: Global: Ophthalmic Drugs Industry: SWOT Analysis
  • Figure 102: Global: Ophthalmic Drugs Industry: Value Chain Analysis
  • Figure 103: Global: Ophthalmic Drugs Industry: Porter's Five Forces Analysis

List of Tables

  • Table 1: Global: Ophthalmic Drugs Market: Key Industry Highlights, 2024 and 2033
  • Table 2: Global: Ophthalmic Drugs Market Forecast: Breakup by Type (in Million USD), 2025-2033
  • Table 3: Global: Ophthalmic Drugs Market Forecast: Breakup by Drug Class (in Million USD), 2025-2033
  • Table 4: Global: Ophthalmic Drugs Market Forecast: Breakup by Indication (in Million USD), 2025-2033
  • Table 5: Global: Ophthalmic Drugs Market Forecast: Breakup by Dosage Form (in Million USD), 2025-2033
  • Table 6: Global: Ophthalmic Drugs Market Forecast: Breakup by Distribution Channel (in Million USD), 2025-2033
  • Table 7: Global: Ophthalmic Drugs Market Forecast: Breakup by Region (in Million USD), 2025-2033
  • Table 8: Global: Ophthalmic Drugs Market: Competitive Structure
  • Table 9: Global: Ophthalmic Drugs Market: Key Players